news release

BURLINGTON, Mass.--(BUSINESS WIRE)--Sep. 3, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that management will participate in two upcoming investor conferences.

John Tucker, Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16 at 1:00pm EDT.

Investors may register for the conference here.

Mr. Tucker is also scheduled to participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17 at 12:00pm EDT.

A live webcast of both sessions can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005278/en/

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com

Media:
Kate Coyle
ICR Inc., 203-682-8210
kate.coyle@icrinc.com

Source: scPharmaceuticals Inc.